Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6Neoplasm Metastasis 2Colorectal Neoplasms 2Solid Tumor 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Osteosarcoma 1Neuroblastoma 1Gastrointestinal Neoplasms 1Borderline Resectable Pancreatic Cancer 1Biliary Tract Neoplasms 1Advanced Esophageal Squamous Cell Cancer 1

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2irinotecan sucrosofate 1folfirinox 1camrelizumab 1Taxes 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Borderline Resectable Pancreatic Cancer × irinotecan sucrosofate × Clear all
NCT06345300 2024-04-03

NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Unknown
40 enrolled
Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡